Turofexorate isopropyl

Turofexorate isopropyl (FXR-450) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM[1].

Product Specifications

CAS Number

[629664-81-9]

Product Name Alternative

FXR-450; XL335; WAY-362450

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Autophagy; FXR

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/WAY-362450.html

Purity

99.77

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 56°C)

Smiles

O=C(C1=CN(C(C2=CC=C(F)C(F)=C2)=O)CC(C)(C)C3=C1NC4=C3C=CC=C4)OC(C)C

Molecular Formula

C25H24F2N2O3

Molecular Weight

438.47

Precautions

H315, H319, H335

References & Citations

[1]Flatt B, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) . J Med Chem. 2009 Feb 26;52 (4) :904-7.|[2]Evans MJ, et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296 (3) :G543-52.|[3]Hartman HB, et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res. 2009 Jun;50 (6) :1090-100.